# Cambridge Cognition win £1.1 million eCOA contract for rare blood disease trial

- Link: https://www.directorstalkinterviews.com/cambridge-cognition-win-1.1-million-ecoa-contract-for-rare-blood-disease-trial/4121087287
- Published: 2022-10-19T07:16:30+01:00
- Author: Giles

**Cambridge Cognition Holdings Plc** ([LON:COG](https://www.directorstalkinterviews.com/company/cambridge-cognition-holdings-plc/cog.l)),
which develops and markets digital solutions to assess brain health, has announced
that it has won a £1.1m contract with a major pharmaceutical company to provide 
electronic clinical outcome assessments (“eCOA”) and hardware for a rare blood disease
study running over the next two years. The new contract, with an existing customer,
is for a mixture of eCOA licenses, services and hardware to support an upcoming 
clinical trial.

As a leader in digital outcome assessments, Cambridge Cognition primarily provides
cognitive measures and eCOA solutions for clinical trials in central nervous systems
disorders. Impressed by Cambridge Cognition’s expertise and performance in handling
multi-site-multi-language studies, the customer has selected the Company to be the
eCOA provider for this trial. This recognition is important for the Company as the
provision of eCOA for clinical trials is a sizeable growth market, valued at over
US$1bn per annum and growing at more than 15% according to market research^(1). 

Cambridge Cognition has been contracted to provide the platform and the hardware
for capturing participants’ experiences as well as their responses to standardised
questionnaires and scales. Cambridge Cognition’s experienced clinical project management
team will work closely with the customer to ensure successful use of the software
and devices. 

> **Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:**
> “Cambridge Cognition has a strong history of delivering cognitive assessments 
> in the field, traditionally in clinics and now also at home. We are pleased to
> see this new order from an existing client, our reputation for quality, service
> and scientific rigour is enabling us to win eCOA-only clinical trials.”

**References**

1.     GrandView Research 2018 eCOA Report

Cambridge Cognition is a technology company developing digital health products to
better understand, detect and treat conditions affecting brain health. The Company’s
software products assess cognitive health in patients worldwide to improve clinical
trial outcomes, identify and stratify patients early and improve global efficiency
in pharmaceutical and healthcare industries.

Share on:
